newscontact us

TotipotentRX and ThermoGenesis Announce Successful Launch of Bone Marrow Transplant Program

First Successful ABO-Incompatible Transplant Using ThermoGenesis’ Breakthrough AXP(R) Platform

RANCHO CORDOVA, Calif. and LOS ANGELES and NEW DELHI, India, Aug. 8, 2013 (GLOBE NEWSWIRE) — TotipotentRX Corporation (“TotiRX”), Fortis Memorial Research Institute (“Fortis”) and ThermoGenesis Corp. (Nasdaq:KOOL) today announced the successful launch of their pediatric bone marrow transplant program at the Fortis-TotiRX Centre for Cellular Medicine in New Delhi, India. This week, the new program achieved its first 100-day survival milestone following an allogeneic bone marrow engraftment in a pediatric patient with aplastic anemia using a donor with ABO-incompatible bone marrow having a major blood group mismatch (Patient B+ve, Donor A+ve). The successful transplant was performed using the AXP® AutoXpress® Platform (“AXP”), and bone marrow software, a FDA and Drug Controller General of India (“DCGI”) approved cell processing platform from ThermoGenesis Corp.

080813 Toti-Fortis Joint Release re BMT Final (2)